Long-acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population-based cohort study.

ABSTRACT:

Aims

The risk of diabetic nephropathy among patients with type 2 diabetes (T2D) can be reduced through optimal glycaemic control. It is not known if the pharmacological properties of long-acting insulin analogues may reduce the risk of diabetic complications compared with neutral protamine Hagedorn (NPH) insulin. We compared the risk of diabetic nephropathy associated with the use of long-acting insulin analogues with the use of intermediate-acting NPH insulin among patients with T2D.

Materials and methods

We conducted a retrospective cohort study using an active-comparator, new user design and the United Kingdom's Clinical Practice Research Datalink AURUM. Our primary outcome was incident diabetic nephropathy, and our secondary outcomes were chronic kidney disease (CKD) and

SUBMITTER: Brillinger J 

PROVIDER: S-EPMC12916077 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature